Acumen Pharmaceuticals
ABOS
41 hedge funds and large institutions have $357M invested in Acumen Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
59.43% more ownership
Funds ownership: 0% → 59.43% (+59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$163M |
| 2 |
BlackRock
New York
|
+$47.7M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$26.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$15.6M |
Top Sellers
ABOS Hedge Fund Activity: Q3 2021 in Review
41 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q3 2021, worth a combined $357M.
Buyers outnumbered sellers: 41 funds opened new ABOS positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $163M.
- 41 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $357M of Acumen Pharmaceuticals stock for Q3 2021.
- 41 funds opened new Acumen Pharmaceuticals positions in Q3 2021 and 0 closed out, a net change of +41 holders.
- The largest Acumen Pharmaceuticals buyer in Q3 2021 was RA Capital Management, an estimated $163M added.
Based on aggregated 13F filings for Q3 2021.